GreenLight Biosciences’ $102 Million Series D Funding Round

Foley Hoag LLP represented GreenLight Biosciences.

GreenLight Biosciences, a Boston, Massachusetts-based RNA vaccine and drug developer, closed its $102 million Series D funding round led by Morningside Ventures. S2G Ventures, Cormorant Asset Management, Continental Grain Company, Fall Line Capital, Tao Capital Partners, Baird Capital, MLS Capital Fund II, Lewis and Clark AgriFood, and Lupa Systems also joined the round. The funding will be used to expand production and accelerate development and commercialization of GreenLight’s pipeline of products.

GreenLight develops sustainable solutions to address some of the biggest issues facing our planet today. The company’s RNA-based vaccines offer tremendous potential to address pandemics like COVID-19, because of shorter preclinical development times compared to traditional vaccines. Its pipeline of RNA-based agricultural products will help farmers create greener, cleaner crops by precisely targeting a specific pest with non-toxic biocontrols, and without harming beneficial insects or leaving residues in the soil or water.

The Foley Hoag team was led by David Broadwin (Picture) and included Erica Harrington and Patricia Pérez Elías.

Involved fees earner: David Broadwin – Foley Hoag;

Law Firms: Foley Hoag;

Clients: GreenLight Biosciences;


Author: Ambrogio Visconti